newsfilter
← Latest News
PR Newswire·

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

Company Pipeline to Focus on Cardiometabolic Disease Cash and Cash Equivalents to Fund the Company into 2024 BOSTON, March 30, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage